Clinical and economic outcomes in respiratory tract infections: The impact of bacterial resistance.
Drug acquisition cost is an important component in the analysis of economic and clinical outcomes in the treatment of respiratory tract infections (RTIs). However, bacterial resistance has emerged as a crucial variable that must also be considered. Drug-resistant infections result in more expensive drug therapy, longer hospital stays, and increased mortality. The high prevalence of community-acquired pneumonia (CAP), as well as the continuing growth in resistant pathogens, make RTIs an appropriate model for studying methods of cost-containment without sacrificing clinical outcome. The University of Kentucky Medical Center has developed a uniform CAP treatment pathway to minimize costs and maximize outcomes. First-line therapy in this model is doxycycline monotherapy, high-dose amoxicillin plus azithromycin, or levofloxacin monotherapy. One major future concern in selecting antibacterial agents for CAP is the spread of macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae.
Rapp
Robert P
RP
University of Kentucky, Lexington, 40536, USA.
D000658:Amoxicillin / Q000191:economics / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use; D017963:Azithromycin / Q000191:economics / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000191:economics* / Q000382:microbiology; D004318:Doxycycline / Q000191:economics / Q000627:therapeutic use; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D006801:Humans; D007629:Kentucky; D064704:Levofloxacin; D015242:Ofloxacin / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000191:economics* / Q000382:microbiology; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000191:economics / Q000382:microbiology; D013296:Streptococcus pneumoniae / Q000187:drug effects; D016896:Treatment Outcome; D014481:United States
D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D000658:Amoxicillin; D017963:Azithromycin; D015242:Ofloxacin; D004318:Doxycycline